A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis

This study is currently recruiting participants.
Verified May 2013 by Hoffmann-La Roche
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche
ClinicalTrials.gov Identifier:
NCT01194570
First received: August 28, 2010
Last updated: May 13, 2013
Last verified: May 2013
  Purpose

This randomized, parallel group, double-blind, placebo controlled study will evaluate the efficacy and safety of ocrelizumab in patients with primary progressive multiple sclerosis. Eligible patients will be randomized 2 : 1 to receive either ocrelizumab (300 mg intravenously, 2 infusions separated by 14 days in each treatment cycle) or placebo. The blinded treatment period will be at least 120 weeks, followed by open label treatment for patients in both groups who in the opinion of the investigator could benefit from further or newly initiated ocrelizumab treatment. Anticipated time on study treatment is up to 5.5 years.


Condition Intervention Phase
Multiple Sclerosis, Primary Progressive
Drug: ocrelizumab
Drug: Placebo
Drug: methylprednisolone
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Phase III, Multicentre, Randomized, Parallel-group, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis

Resource links provided by NLM:


Further study details as provided by Hoffmann-La Roche:

Primary Outcome Measures:
  • Efficacy: Time to onset of sustained disability progression, defined as an increase in Expanded Disability Status Scale (EDSS) score that is sustained for at least 12 weeks [ Time Frame: up to 5.5 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Time to sustained disability progression, defined as an increase in EDSS score that is sustained for at least 24 weeks [ Time Frame: up to 5.5 years ] [ Designated as safety issue: No ]
  • Change in timed 25-foot walk [ Time Frame: from baseline to Week 120 ] [ Designated as safety issue: No ]
  • Change in total volume of T2 lesions on magnetic resonance imaging (MRI) scans of the brain [ Time Frame: from baseline to Week 180 ] [ Designated as safety issue: No ]
  • Safety and tolerability: Incidence of adverse events [ Time Frame: up to 5.5 years ] [ Designated as safety issue: No ]

Estimated Enrollment: 630
Study Start Date: March 2011
Estimated Study Completion Date: November 2017
Estimated Primary Completion Date: November 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A Drug: ocrelizumab
2 intravenous infusions of 300 mg separated by 14 days in each treatment cycle
Drug: methylprednisolone
100 mg iv 30 minutes prior to ocrelizumab or placebo infusion
Placebo Comparator: B Drug: Placebo
Ocrelizumab placebo, 2 infusions separated by 14 days in each treatment cycle
Drug: methylprednisolone
100 mg iv 30 minutes prior to ocrelizumab or placebo infusion

  Eligibility

Ages Eligible for Study:   18 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adult patients, 18-55 years of age
  • Primary Progressive Multiple Sclerosis (according to revised McDonald criteria)
  • Expanded Disability Status Scale (EDSS) 3 to 6.5 points
  • Disease duration from onset of MS symptoms < 15 years if EDSS > 5.0, < 10 years if EDSS >/= 5.0
  • Sexually active male and female patients of reproductive potential must use two methods of contraception throughout the study treatment phase and for 48 weeks after the last dose

Exclusion Criteria:

  • History of relapsing remitting multiple sclerosis, secondary progressive, or progressive relapsing multiple sclerosis at screening
  • Contraindications for Magnetic Resonance Imaging (MRI)
  • Known presence of other neurologic disorders
  • Known active infection or history of or presence of recurrent or chronic infection
  • History of cancer, including solid tumors and hematological malignancies (except for basal cell, in situ squamous cell carcinomas of the skin and in situ carcinoma of the cervix that have been excised and resolved)
  • Previous treatment with B-cell targeted therapies (e.g. rituximab, ocrelizumab, atacicept, belimumab, or ofatumumab)
  • Any previous treatment with lymphocyte trafficking blockers, with alemtuzumab, anti-CD4, cladribine, cyclophosphamide, mitoxantrone, azathioprine, mycophenolate mofetil, cyclosporine, methotrexate, total body irradiation, or bone marrow transplantation
  • Any concomitant disease that may require chronic treatment with systemic corticosteroids or immunosuppressants during the course of the study
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01194570

Contacts
Contact: Please reference Study ID Number: WA25046 www.roche.com/about_roche/roche_worldwide.htm 888-662-6728 (U.S. Only) genentechclinicaltrials@druginfo.com

  Hide Study Locations
Locations
United States, Arizona
Active, not recruiting
Phoenix, Arizona, United States, 85013
Active, not recruiting
Phoenix, Arizona, United States, 85018
Active, not recruiting
Phoenix, Arizona, United States, 85050
Active, not recruiting
Scottsdale, Arizona, United States, 85259
United States, California
Active, not recruiting
Newport Beach, California, United States, 92663
Active, not recruiting
Oakland, California, United States, 94609
Active, not recruiting
Sacramento, California, United States, 95817
Active, not recruiting
San Francisco, California, United States, 94143
United States, Colorado
Active, not recruiting
Aurora, Colorado, United States, 80045
United States, Florida
Terminated
Bradenton, Florida, United States, 34205
Terminated
Maitland, Florida, United States, 32751
Active, not recruiting
Miami, Florida, United States, 33136
Terminated
Tampa, Florida, United States, 33609
Active, not recruiting
Vero Beach, Florida, United States, 32960
United States, Georgia
Terminated
Atlanta, Georgia, United States, 30327
Terminated
Atlanta, Georgia, United States, 30322
United States, Illinois
Terminated
Chicago, Illinois, United States, 60611
United States, Kansas
Active, not recruiting
Kansas City, Kansas, United States, 66160
Active, not recruiting
Lenexa, Kansas, United States, 66214
United States, Michigan
Active, not recruiting
Detroit, Michigan, United States, 48201
Active, not recruiting
Detroit, Michigan, United States, 48202
Active, not recruiting
Farmington Hills, Michigan, United States, 48334
Active, not recruiting
Minneapolis, Michigan, United States, 55455
United States, Minnesota
Terminated
Golden Valley, Minnesota, United States, 55422
United States, Missouri
Active, not recruiting
St. Louis, Missouri, United States, 63110
United States, New Jersey
Active, not recruiting
Teaneck, New Jersey, United States, 07666
United States, New Mexico
Active, not recruiting
Albuquerque, New Mexico, United States, 87131
United States, New York
Terminated
Albany, New York, United States, 12208
Completed
Mineola, New York, United States, 11501
Active, not recruiting
New York, New York, United States, 10029
Active, not recruiting
New York, New York, United States, 10021
Active, not recruiting
Patchogue, New York, United States, 11772
Terminated
Rochester, New York, United States, 14642
Active, not recruiting
Stony Brook, New York, United States, 11794
United States, North Carolina
Terminated
Advance, North Carolina, United States, 27006
Active, not recruiting
Charlotte, North Carolina, United States, 28207
Active, not recruiting
Raleigh, North Carolina, United States, 27607-6010
United States, Ohio
Active, not recruiting
Columbus, Ohio, United States, 43210
United States, Oklahoma
Active, not recruiting
Oklahoma City, Oklahoma, United States, 73104
United States, Oregon
Terminated
Tualatin, Oregon, United States, 97062
United States, Pennsylvania
Active, not recruiting
Philadelphia, Pennsylvania, United States, 19104
United States, Rhode Island
Active, not recruiting
Providence, Rhode Island, United States, 02905
United States, Tennessee
Active, not recruiting
Memphis, Tennessee, United States, 38120
United States, Texas
Active, not recruiting
Dallas, Texas, United States, 75390-9063
Active, not recruiting
Houston, Texas, United States, 77030
Terminated
Round Rock, Texas, United States, 78681
United States, Virginia
Active, not recruiting
Henrico, Virginia, United States, 23226
United States, Washington
Active, not recruiting
Seattle, Washington, United States, 98122
United States, Wisconsin
Terminated
Milwaukee, Wisconsin, United States, 53215
Australia
Active, not recruiting
Fitzroy, Australia, 3065
Terminated
Heidelberg, Australia, 3084
Active, not recruiting
Hobart, Australia, 7000
Austria
Active, not recruiting
Innsbruck, Austria, 6020
Active, not recruiting
Linz, Austria, 4021
Active, not recruiting
Linz, Austria, 4020
Active, not recruiting
Salzburg, Austria, 5020
Terminated
Villach, Austria, 9500
Active, not recruiting
Wien, Austria, 1090
Belgium
Active, not recruiting
La Louviere, Belgium, 7100
Terminated
Leuven, Belgium, 3000
Active, not recruiting
Sijsele-damme, Belgium, 8340
Brazil
Active, not recruiting
Belo Horizonte, Brazil, 30150-221
Active, not recruiting
Goiânia, Brazil, 74605-020
Active, not recruiting
Porto Alegre, Brazil, 90610-000
Active, not recruiting
Rio de Janeiro, Brazil, 22290-240
Bulgaria
Terminated
Pleven, Bulgaria, 5800
Active, not recruiting
Sofia, Bulgaria, 1309
Active, not recruiting
Sofia, Bulgaria, 1113
Terminated
Sofia, Bulgaria, 1407
Canada, Alberta
Active, not recruiting
Calgary, Alberta, Canada, T2N 2T9
Canada, British Columbia
Active, not recruiting
Vancouver, British Columbia, Canada, V6T 2B5
Canada, Manitoba
Active, not recruiting
Winnipeg, Manitoba, Canada, R8A 1R9
Canada, Ontario
Active, not recruiting
Ottawa, Ontario, Canada, K1H 8L6
Active, not recruiting
Toronto, Ontario, Canada, M5B 1W8
Terminated
Toronto, Ontario, Canada, M4N 3M5
Canada, Quebec
Active, not recruiting
Greenfield Park, Quebec, Canada, J4V 2J2
Active, not recruiting
Montreal, Quebec, Canada, H3A 2B4
Czech Republic
Active, not recruiting
Brno, Czech Republic, 625 00
Active, not recruiting
Praha 2, Czech Republic, 128 08
Active, not recruiting
Teplice, Czech Republic, 415 29
Denmark
Terminated
Sonderborg, Denmark, 6400
Finland
Active, not recruiting
Helsinki, Finland, 00290
Active, not recruiting
Tampere, Finland, 33520
Recruiting
Turku, Finland, 20100
Active, not recruiting
Turku, Finland, 20520
France
Terminated
Besancon, France, 25030
Active, not recruiting
Bordeaux, France, 33076
Active, not recruiting
Caen, France, 14033
Active, not recruiting
Clermont-ferrand, France, 63003
Active, not recruiting
Lille, France, 59037
Active, not recruiting
Lyon, France, 69394
Active, not recruiting
Marseille, France, 13005
Active, not recruiting
Montpellier, France, 34295
Active, not recruiting
Nancy, France, 54035
Active, not recruiting
Nantes, France, 44805
Active, not recruiting
Nice, France, 06002
Active, not recruiting
Nimes, France, 30029
Active, not recruiting
Paris, France, 75651
Active, not recruiting
Paris, France, 75019
Active, not recruiting
Poissy, France, 78300
Active, not recruiting
Reims, France, 51092
Active, not recruiting
Strasbourg, France, 67091
Active, not recruiting
Toulouse, France, 31059
Germany
Active, not recruiting
Bayreuth, Germany, 95445
Active, not recruiting
Berg, Germany, 82335
Active, not recruiting
Berlin, Germany, 10117
Active, not recruiting
Berlin, Germany, 13347
Active, not recruiting
Bochum, Germany, 06097
Active, not recruiting
Dresden, Germany, 01307
Active, not recruiting
Düsseldorf, Germany, 40225
Active, not recruiting
Frankfurt, Germany, 60528
Active, not recruiting
GIEßEN, Germany, 35385
Active, not recruiting
Heidelberg, Germany, 69115
Active, not recruiting
Köln, Germany, 51067
Active, not recruiting
Leipzig, Germany, 04103
Terminated
Marburg, Germany, 35032
Active, not recruiting
Munich, Germany, 81675
Active, not recruiting
Münster, Germany, 48149
Active, not recruiting
Regensburg, Germany, 93053
Active, not recruiting
Tübingen, Germany, 72076
Active, not recruiting
ULM, Germany, 89081
Active, not recruiting
Wiesbaden, Germany, 65191
Greece
Active, not recruiting
Athens, Greece, 11525
Active, not recruiting
Thessaloniki, Greece, 54636
Active, not recruiting
Thessaloniki, Greece, 57010
Hungary
Active, not recruiting
Budapest, Hungary, 1145
Active, not recruiting
Budapest, Hungary, 1204
Terminated
Budapest, Hungary, 1033
Active, not recruiting
Esztergom, Hungary, 2500
Active, not recruiting
Pécs, Hungary, 7623
Active, not recruiting
Szeged, Hungary, 6720
Recruiting
Veszprem, Hungary, 8200
Israel
Active, not recruiting
Ashkelon, Israel, 78278
Terminated
Haifa, Israel, 31048
Active, not recruiting
Petach Tikva, Israel, 49100
Active, not recruiting
Ramat-gan, Israel, 52621
Active, not recruiting
Safed, Israel, 13100
Active, not recruiting
Tel Aviv, Israel, 64239
Italy
Active, not recruiting
Cagliari, Italy, 09126
Active, not recruiting
Genova, Italy, 16132
Active, not recruiting
Milano, Italy, 20132
Active, not recruiting
Orbassano, Italy, 10043
Lithuania
Active, not recruiting
Kaunas, Lithuania, 50009
Active, not recruiting
Klaipeda, Lithuania, 92288
Active, not recruiting
Siauliai, Lithuania, LT-76231
Mexico
Active, not recruiting
Aguascalientes, Mexico, 20127
Active, not recruiting
Mexico, Mexico, 03600
Active, not recruiting
Mexico City, Mexico, 14390
Active, not recruiting
Monterrey, Mexico, 64620
Netherlands
Active, not recruiting
Rotterdam, Netherlands, 3015 CE
Active, not recruiting
Sittard-geleen, Netherlands, 6162 BG
New Zealand
Active, not recruiting
Hamilton, New Zealand, 3240
Active, not recruiting
Wellington, New Zealand, 6021
Norway
Active, not recruiting
Oslo, Norway, 0407
Peru
Active, not recruiting
Bellavista, Peru, Callao 2
Active, not recruiting
Lima, Peru, Lima 1
Active, not recruiting
San Isidro, Peru, Lima 27
Poland
Active, not recruiting
Bialystok, Poland, 15-402
Active, not recruiting
Jaroslaw, Poland, 37-500
Active, not recruiting
Katowice, Poland, 40-752
Active, not recruiting
Katowice, Poland, 40-594
Active, not recruiting
Konskie, Poland, 26-200
Active, not recruiting
Lodz, Poland, 90-153
Active, not recruiting
Lublin, Poland, 20-954
Terminated
Plewiska, Poland, 62-064
Terminated
Poznan, Poland, 60-355
Portugal
Active, not recruiting
Almada, Portugal, 2801-951
Active, not recruiting
Amadora, Portugal, 2720-276
Active, not recruiting
Coimbra, Portugal, 3041-801
Active, not recruiting
Coimbra, Portugal, 3000-075
Active, not recruiting
Lisboa, Portugal, 1649-035
Terminated
Lisboa, Portugal, 1169-050
Active, not recruiting
Porto, Portugal, 4099-001
Romania
Active, not recruiting
Bucharest, Romania, 011461
Terminated
Bucharest, Romania, 060011
Active, not recruiting
Campulung, Romania, 115100
Active, not recruiting
Targu Mures, Romania, 50
Active, not recruiting
Timisoara, Romania, 300736
Russian Federation
Active, not recruiting
Kazan, Russian Federation, 420103
Spain
Active, not recruiting
Alicante, Spain, 03010
Active, not recruiting
Barcelona, Spain, 08032
Active, not recruiting
Barcelona, Spain, 08025
Active, not recruiting
Barcelona, Spain, 08035
Active, not recruiting
Barcelona, Spain, 08003
Active, not recruiting
Bilbao, Spain, 48013
Active, not recruiting
Girona, Spain, 17007
Active, not recruiting
Madrid, Spain, 28040
Active, not recruiting
Madrid, Spain, 28034
Active, not recruiting
Madrid, Spain, 28006
Active, not recruiting
Malaga, Spain, 29010
Active, not recruiting
San Sebastian, Spain, 20014
Active, not recruiting
Santiago de Compostela, Spain, 15706
Active, not recruiting
Sevilla, Spain, 41009
Switzerland
Active, not recruiting
Basel, Switzerland, 4031
Active, not recruiting
Lugano, Switzerland, 6903
Terminated
Zürich, Switzerland, 8091
Turkey
Terminated
Ankara, Turkey, 06100
Terminated
Edirne, Turkey, 22030
Terminated
Kocaeli, Turkey, 41380
Ukraine
Active, not recruiting
Chernivtsi, Ukraine, 58000
Active, not recruiting
Dnipropetrovsk, Ukraine, 49044
Active, not recruiting
Dnipropetrovsk, Ukraine, 49027
Active, not recruiting
Kharkiv, Ukraine, 61018
Active, not recruiting
Kharkov, Ukraine, 61068
Active, not recruiting
Kiev, Ukraine, 04107
Active, not recruiting
Kyiv, Ukraine, 03110
Terminated
Lutsk, Ukraine, 43024
Active, not recruiting
Lutsk, Ukraine, 43024
Active, not recruiting
Lviv, Ukraine, 79010
Active, not recruiting
Odesa, Ukraine, 65117
Terminated
Ternopil, Ukraine, 46027
Active, not recruiting
Vinnytsya, Ukraine, 21018
United Kingdom
Active, not recruiting
Liverpool, United Kingdom, L9 1AE
Active, not recruiting
London, United Kingdom, E1 2ES
Active, not recruiting
London, United Kingdom, SE5 9RS
Active, not recruiting
Newcastle Upon Tyne, United Kingdom, NE1 4LP
Active, not recruiting
Nottingham, United Kingdom, NG7 2UH
Uruguay
Active, not recruiting
Indianapolis, Uruguay, 46202
Sponsors and Collaborators
Hoffmann-La Roche
Investigators
Study Director: Clinical Trials Hoffmann-La Roche
  More Information

No publications provided

Responsible Party: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT01194570     History of Changes
Other Study ID Numbers: WA25046, 2010-020338-25
Study First Received: August 28, 2010
Last Updated: May 13, 2013
Health Authority: Peru: Instituto Nacional de Salud (INS)

Additional relevant MeSH terms:
Multiple Sclerosis
Sclerosis
Multiple Sclerosis, Chronic Progressive
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Pathologic Processes
Methylprednisolone acetate
Prednisolone acetate
Methylprednisolone
Methylprednisolone Hemisuccinate
Prednisolone
Prednisolone hemisuccinate
Prednisolone phosphate
Anti-Inflammatory Agents
Therapeutic Uses
Pharmacologic Actions
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Central Nervous System Agents
Gastrointestinal Agents
Neuroprotective Agents
Protective Agents
Glucocorticoids
Hormones

ClinicalTrials.gov processed this record on May 21, 2013